Article · 13 Nov 2026
ArticlePublished 2014
Novel Agents for the Treatment of Pancreatic Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Metastatic pancreatic cancer continues to be a difficult disease to treat because of its aggressive nature, advanced stage atpresentation and lack of treatment options. There is a need for the development of new agents directed against novel targetsto improve outcomes for these patients. At the 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal CancersSymposium phase I/II trials provided information on three novel strategies for treating metastatic pancreatic cancer.Immunotherapy in the form of a vaccine (GVAX) followed with an immune stimulator (CRS-207) showed extended survival(Abstract #177). A monoclonal antibody (NEO-102) targeting MUC5AC also showed activity and was well tolerated (Abstract#243). A heat shock protein 90 (HSP90) inhibitor (ganetespib) showed modest effects but was well tolerated making itavailable for use with conventional chemotherapy (Abstract #297). The details of these presentations will be discussed.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of the Pancreas.
Article · 25 Jun 2026
Comparative outcomes of Open and Laparoscopic drainage in Walled off Pancreatic Necrosis
Article · 24 Feb 2026
Xanthogranulomatous Pancreatitis Showing Overlapping
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of the Pancreas
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Muhammad Wasif Saif”
- BylineArticles whose byline prints “Gregory T Brennan”
- BylineArticles whose byline prints “Valerie Relias”